Merck KGaA (MKGAF)
(Delayed Data from OTC)
$157.08 USD
-8.25 (-4.99%)
Updated Apr 26, 2024 01:14 PM ET
4-Sell of 5 4
A Value F Growth D Momentum C VGM
Price, Consensus and EPS Surprise
MKGAF 157.08 -8.25(-4.99%)
Will MKGAF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MKGAF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MKGAF
HEXO (HEXO) Reports Q3 Loss, Lags Revenue Estimates
Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates
MKGAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates
Other News for MKGAF
908 Devices: Rare Early-Stage Bioprocess Investment Opportunity
Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities
Merck KGaA: Moving To A Hold As 2025 Targets Are Now Doubtful
Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript
Merck KGaA Non-GAAP EPS of €8.49, revenue of €20.99B; initiates FY24 outlook